<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_medium=rss&amp;ff=20241220231241&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_medium=rss&amp;ff=20241220231241&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sat, 21 Dec 2024 04:12:43 +0000</lastbuilddate>
<pubDate>Fri, 20 Dec 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Trustworthy implementation of artificial intelligence in cardiology: a roadmap of the European Society of Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39704781/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241220231241&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 20:ehae748. doi: 10.1093/eurheartj/ehae748. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39704781/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241220231241&v=2.18.0.post9+e462414">39704781</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae748>10.1093/eurheartj/ehae748</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39704781</guid>
<pubDate>Fri, 20 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Folkert W Asselbergs</dc:creator>
<dc:creator>Thomas F Lüscher</dc:creator>
<dc:date>2024-12-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Trustworthy implementation of artificial intelligence in cardiology: a roadmap of the European Society of Cardiology</dc:title>
<dc:identifier>pmid:39704781</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae748</dc:identifier>
</item>
<item>
<title>Activation of Imprinted Gene &lt;em>;PW1&lt;/em>; Promotes Cardiac Fibrosis After Ischemic Injury</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39704066/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241220231241&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study demonstrates that Pw1 imprinting is disrupted after injury and reveals a novel role for the downstream target PFAS in ECM production and cardiac fibrogenesis. Targeting the PW1/PFAS signaling pathway presents a promising therapeutic strategy for improving cardiac repair after injury.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 20. doi: 10.1161/CIRCULATIONAHA.124.070738. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiac fibrosis, characterized by excessive extracellular matrix (ECM) deposition in the myocardium, is an important target for heart disease treatments. <i>Pw1</i> (paternally expressed gene 3) is an imprinted gene expressed from the paternal allele, and de novo purine biosynthesis (DNPB) is a crucial pathway for nucleotide synthesis. However, the roles of PW1 and DNPB in ECM production by cardiac fibroblasts during myocardial ischemia are not yet understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: To induce myocardial damage, we performed left anterior descending coronary artery ligation. We generated <i>Pw1</i><sup><i>CreER-2A-eGFP</i></sup> and <i>Pw1</i><sup><i>2A-CreER</i></sup> knock-in mouse lines to evaluate the expression of the 2 <i>Pw1</i> alleles in normal and injured hearts. Bisulfite sequencing was used to analyze the DNA methylation of the <i>Pw1</i> imprinting control region. We identified the phosphoribosylformylglycinamidine synthase (<i>Pfas</i>) gene, encoding the DNPB enzyme PFAS, as a direct target of PW1 using chromatin immunoprecipitation sequencing and real-time quantitative polymerase chain reaction. The role of DNPB in ECM production and cardiac fibrosis after injury was examined in vitro using cultured cardiac fibroblasts and in vivo with <i>Pfas</i>-deficient mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Our study demonstrates that myocardial infarction reduces DNA methylation at the imprinting control region of the maternally imprinted gene <i>Pw1</i>, triggering a switch from monoallelic imprinting to biallelic expression of <i>Pw1</i> in cardiac fibroblasts. In activated cardiac fibroblasts, increased <i>Pw1</i> expression promotes purine biosynthesis and induces ECM production by transcriptionally activating the DNPB factor <i>Pfas</i>. We identified that DNPB is essential for ECM production in activated fibroblasts and that loss of <i>Pfas</i> in fibroblasts limits cardiac fibrosis and improves heart function after injury.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study demonstrates that <i>Pw1</i> imprinting is disrupted after injury and reveals a novel role for the downstream target PFAS in ECM production and cardiac fibrogenesis. Targeting the PW1/PFAS signaling pathway presents a promising therapeutic strategy for improving cardiac repair after injury.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39704066/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241220231241&v=2.18.0.post9+e462414">39704066</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070738>10.1161/CIRCULATIONAHA.124.070738</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39704066</guid>
<pubDate>Fri, 20 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Shan Kou</dc:creator>
<dc:creator>Zhengkai Lu</dc:creator>
<dc:creator>Defang Deng</dc:creator>
<dc:creator>Min Ye</dc:creator>
<dc:creator>Yu Sui</dc:creator>
<dc:creator>Lieyang Qin</dc:creator>
<dc:creator>Teng Feng</dc:creator>
<dc:creator>Zhen Jiang</dc:creator>
<dc:creator>Jufeng Meng</dc:creator>
<dc:creator>Chao-Po Lin</dc:creator>
<dc:creator>Xiajun Li</dc:creator>
<dc:creator>Chen Liu</dc:creator>
<dc:creator>Juan Tang</dc:creator>
<dc:creator>Hui Zhang</dc:creator>
<dc:date>2024-12-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Activation of Imprinted Gene &lt;em>;PW1&lt;/em>; Promotes Cardiac Fibrosis After Ischemic Injury</dc:title>
<dc:identifier>pmid:39704066</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070738</dc:identifier>
</item>
<item>
<title>Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39701102/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241220231241&amp;v=2.18.0.post9+e462414
      <description>The canonical model of tumor suppressor gene (TSG)-mediated oncogenesis posits that loss of both alleles is necessary for inactivation. Here, through allele-specific analysis of sequencing data from 48,179 cancer patients, we define the prevalence, selective pressure for, and functional consequences of biallelic inactivation across TSGs. TSGs largely assort into distinct classes associated with either pan-cancer (Class 1) or lineage-specific (Class 2) patterns of selection for biallelic loss,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 12:S0092-8674(24)01327-8. doi: 10.1016/j.cell.2024.11.010. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The canonical model of tumor suppressor gene (TSG)-mediated oncogenesis posits that loss of both alleles is necessary for inactivation. Here, through allele-specific analysis of sequencing data from 48,179 cancer patients, we define the prevalence, selective pressure for, and functional consequences of biallelic inactivation across TSGs. TSGs largely assort into distinct classes associated with either pan-cancer (Class 1) or lineage-specific (Class 2) patterns of selection for biallelic loss, although some TSGs are predominantly monoallelically inactivated (Class 3/4). We demonstrate that selection for biallelic inactivation can be utilized to identify driver genes in non-canonical contexts, including among variants of unknown significance (VUSs) of several TSGs such as KEAP1. Genomic, functional, and clinical data collectively indicate that KEAP1 VUSs phenocopy established KEAP1 oncogenic alleles and that zygosity, rather than variant classification, is predictive of therapeutic response. TSG zygosity is therefore a fundamental determinant of disease etiology and therapeutic sensitivity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39701102/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241220231241&v=2.18.0.post9+e462414">39701102</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.010>10.1016/j.cell.2024.11.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39701102</guid>
<pubDate>Thu, 19 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Mark Zucker</dc:creator>
<dc:creator>Maria A Perry</dc:creator>
<dc:creator>Samuel I Gould</dc:creator>
<dc:creator>Arielle Elkrief</dc:creator>
<dc:creator>Anton Safonov</dc:creator>
<dc:creator>Rohit Thummalapalli</dc:creator>
<dc:creator>Miika Mehine</dc:creator>
<dc:creator>Debyani Chakravarty</dc:creator>
<dc:creator>A Rose Brannon</dc:creator>
<dc:creator>Marc Ladanyi</dc:creator>
<dc:creator>Pedram Razavi</dc:creator>
<dc:creator>Mark T A Donoghue</dc:creator>
<dc:creator>Yonina R Murciano-Goroff</dc:creator>
<dc:creator>Kristiana Grigoriadis</dc:creator>
<dc:creator>Nicholas McGranahan</dc:creator>
<dc:creator>Mariam Jamal-Hanjani</dc:creator>
<dc:creator>Charles Swanton</dc:creator>
<dc:creator>Yuan Chen</dc:creator>
<dc:creator>Ronglai Shen</dc:creator>
<dc:creator>Sarat Chandarlapaty</dc:creator>
<dc:creator>David B Solit</dc:creator>
<dc:creator>Nikolaus Schultz</dc:creator>
<dc:creator>Michael F Berger</dc:creator>
<dc:creator>Jason Chang</dc:creator>
<dc:creator>Adam J Schoenfeld</dc:creator>
<dc:creator>Francisco J Sánchez-Rivera</dc:creator>
<dc:creator>Ed Reznik</dc:creator>
<dc:creator>Chaitanya Bandlamudi</dc:creator>
<dc:date>2024-12-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer</dc:title>
<dc:identifier>pmid:39701102</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.010</dc:identifier>
</item>
<item>
<title>Engineering and structures of Crimean-Congo hemorrhagic fever virus glycoprotein complexes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39701101/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241220231241&amp;v=2.18.0.post9+e462414
      <description>Crimean-Congo hemorrhagic fever virus (CCHFV) is a tickborne virus that can cause severe disease in humans with case fatality rates of 10%-40%. Although structures of CCHFV glycoproteins GP38 and Gc have provided insights into viral entry and defined epitopes of neutralizing and protective antibodies, the structure of glycoprotein Gn and its interactions with GP38 and Gc have remained elusive. Here, we use structure-guided protein engineering to produce a stabilized GP38-Gn-Gc heterotrimeric...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 10:S0092-8674(24)01325-4. doi: 10.1016/j.cell.2024.11.008. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Crimean-Congo hemorrhagic fever virus (CCHFV) is a tickborne virus that can cause severe disease in humans with case fatality rates of 10%-40%. Although structures of CCHFV glycoproteins GP38 and Gc have provided insights into viral entry and defined epitopes of neutralizing and protective antibodies, the structure of glycoprotein Gn and its interactions with GP38 and Gc have remained elusive. Here, we use structure-guided protein engineering to produce a stabilized GP38-Gn-Gc heterotrimeric glycoprotein complex (GP38-Gn<sup>H-DS</sup>-Gc). A cryo-electron microscopy (cryo-EM) structure of this complex provides the molecular basis for GP38's association on the viral surface, reveals the structure of Gn, and demonstrates that GP38-Gn restrains the Gc fusion loops in the prefusion conformation, facilitated by an N-linked glycan attached to Gn. Immunization with GP38-Gn<sup>H-DS</sup>-Gc conferred 40% protection against lethal IbAr10200 challenge in mice. These data define the architecture of a GP38-Gn-Gc protomer and provide a template for structure-guided vaccine antigen development.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39701101/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241220231241&v=2.18.0.post9+e462414">39701101</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.008>10.1016/j.cell.2024.11.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39701101</guid>
<pubDate>Thu, 19 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Elizabeth McFadden</dc:creator>
<dc:creator>Stephanie R Monticelli</dc:creator>
<dc:creator>Albert Wang</dc:creator>
<dc:creator>Ajit R Ramamohan</dc:creator>
<dc:creator>Thomas G Batchelor</dc:creator>
<dc:creator>Ana I Kuehne</dc:creator>
<dc:creator>Russell R Bakken</dc:creator>
<dc:creator>Alexandra L Tse</dc:creator>
<dc:creator>Kartik Chandran</dc:creator>
<dc:creator>Andrew S Herbert</dc:creator>
<dc:creator>Jason S McLellan</dc:creator>
<dc:date>2024-12-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Engineering and structures of Crimean-Congo hemorrhagic fever virus glycoprotein complexes</dc:title>
<dc:identifier>pmid:39701101</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.008</dc:identifier>
</item>
<item>
<title>The auditory midbrain mediates tactile vibration sensing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39701100/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241220231241&amp;v=2.18.0.post9+e462414
      <description>Vibrations are ubiquitous in nature, shaping behavior across the animal kingdom. For mammals, mechanical vibrations acting on the body are detected by mechanoreceptors of the skin and deep tissues and processed by the somatosensory system, while sound waves traveling through air are captured by the cochlea and encoded in the auditory system. Here, we report that mechanical vibrations detected by the body's Pacinian corpuscle neurons, which are distinguished by their ability to entrain to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 14:S0092-8674(24)01331-X. doi: 10.1016/j.cell.2024.11.014. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Vibrations are ubiquitous in nature, shaping behavior across the animal kingdom. For mammals, mechanical vibrations acting on the body are detected by mechanoreceptors of the skin and deep tissues and processed by the somatosensory system, while sound waves traveling through air are captured by the cochlea and encoded in the auditory system. Here, we report that mechanical vibrations detected by the body's Pacinian corpuscle neurons, which are distinguished by their ability to entrain to high-frequency (40-1,000 Hz) environmental vibrations, are prominently encoded by neurons in the lateral cortex of the inferior colliculus (LCIC) of the midbrain. Remarkably, most LCIC neurons receive convergent Pacinian and auditory input and respond more strongly to coincident tactile-auditory stimulation than to either modality alone. Moreover, the LCIC is required for behavioral responses to high-frequency mechanical vibrations. Thus, environmental vibrations captured by Pacinian corpuscles are encoded in the auditory midbrain to mediate behavior.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39701100/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241220231241&v=2.18.0.post9+e462414">39701100</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.014>10.1016/j.cell.2024.11.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39701100</guid>
<pubDate>Thu, 19 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Erica L Huey</dc:creator>
<dc:creator>Josef Turecek</dc:creator>
<dc:creator>Michelle M Delisle</dc:creator>
<dc:creator>Ofer Mazor</dc:creator>
<dc:creator>Gabriel E Romero</dc:creator>
<dc:creator>Malvika Dua</dc:creator>
<dc:creator>Zoe K Sarafis</dc:creator>
<dc:creator>Alexis Hobble</dc:creator>
<dc:creator>Kevin T Booth</dc:creator>
<dc:creator>Lisa V Goodrich</dc:creator>
<dc:creator>David P Corey</dc:creator>
<dc:creator>David D Ginty</dc:creator>
<dc:date>2024-12-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The auditory midbrain mediates tactile vibration sensing</dc:title>
<dc:identifier>pmid:39701100</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.014</dc:identifier>
</item>
<item>
<title>From cardiorenal to cardiovascular-kidney-metabolic syndromes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39699246/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241220231241&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 19:ehae775. doi: 10.1093/eurheartj/ehae775. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39699246/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241220231241&v=2.18.0.post9+e462414">39699246</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae775>10.1093/eurheartj/ehae775</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39699246</guid>
<pubDate>Thu, 19 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:date>2024-12-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>From cardiorenal to cardiovascular-kidney-metabolic syndromes</dc:title>
<dc:identifier>pmid:39699246</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae775</dc:identifier>
</item>
<item>
<title>Correction to: Family matters: health policies to tackle cardiomyopathies across Europe</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39699240/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241220231241&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 19:ehae898. doi: 10.1093/eurheartj/ehae898. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39699240/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241220231241&v=2.18.0.post9+e462414">39699240</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae898>10.1093/eurheartj/ehae898</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39699240</guid>
<pubDate>Thu, 19 Dec 2024 06:00:00 -0500</pubDate>
<dc:date>2024-12-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Family matters: health policies to tackle cardiomyopathies across Europe</dc:title>
<dc:identifier>pmid:39699240</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae898</dc:identifier>
</item>
<item>
<title>Covered Stent Correction for Sinus Venosus Atrial Septal Defects, an Emerging Alternative to Surgical Repair: Results of an International Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39697167/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241220231241&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This article details the exponential uptake of covered stent correction for SVASD during the past 5 years. Cardiopulmonary bypass was avoided in the majority of patients, and major complications were infrequent. Prospective registries with standardized definitions, inclusion criteria, and follow-up and comparative studies with surgery are now required to help support the extension of covered stent correction as an alternative standard-of-care option for patients with an SVASD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 19. doi: 10.1161/CIRCULATIONAHA.124.070271. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Covered stent correction for a sinus venosus atrial septal defect (SVASD) was first performed in 2009. This innovative approach was initially viewed as experimental and was reserved for highly selected patients with unusual anatomic variants. In 2016, increasing numbers of procedures began to be performed, and in several centers, it is now offered as a standard of care option alongside surgical repair. However, covered stent correction for SVASD is not recognized by regulatory authorities, and in the minds of many pediatric and adult congenital cardiologists and surgeons, the condition is viewed as treatable only by cardiac surgery with cardiopulmonary bypass.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In April 2023, all centers identified from international conferences, publications, and colleague networks to be undertaking covered stent correction for SVASD were invited to participate in a retrospective audit of their procedures.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Data were received on 381 patients from 54 units over a 12-year period with 90% of procedures being performed over the past 5 years. Balloon-expandable stents (8 types) were used in the majority; self-expanding stents (4 types) were used in 4.5%. The commonest stent was the 10-zig covered Cheatham Platinum stent in 62% of cases. In 10 procedures, the stent embolized requiring surgical retrieval and repair of the defect, resulting in technically successful implantation in 371 of 381 (97.4%). Major complications (surgical drainage of tamponade, pacemaker implantation, surgery for pulmonary vein occlusion, and late stent removal) occurred in 5 patients (1.3%). Repeat catheterization to correct residual leaks was required in 7 patients (1.8%). Thus, 359 of 381 patients (94.2%) had successful correction without major complications or additional catheter interventions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This article details the exponential uptake of covered stent correction for SVASD during the past 5 years. Cardiopulmonary bypass was avoided in the majority of patients, and major complications were infrequent. Prospective registries with standardized definitions, inclusion criteria, and follow-up and comparative studies with surgery are now required to help support the extension of covered stent correction as an alternative standard-of-care option for patients with an SVASD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39697167/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241220231241&v=2.18.0.post9+e462414">39697167</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070271>10.1161/CIRCULATIONAHA.124.070271</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39697167</guid>
<pubDate>Thu, 19 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Eric Rosenthal</dc:creator>
<dc:creator>Shakeel A Qureshi</dc:creator>
<dc:creator>Kothandam Sivakumar</dc:creator>
<dc:creator>Matthew Jones</dc:creator>
<dc:creator>San-Fui Yong</dc:creator>
<dc:creator>Saleha Kabir</dc:creator>
<dc:creator>Pramod Sagar</dc:creator>
<dc:creator>Puthiyedath Thejaswi</dc:creator>
<dc:creator>Sebastien Hascoet</dc:creator>
<dc:creator>Clement Batteux</dc:creator>
<dc:creator>Younes Boudjemline</dc:creator>
<dc:creator>Ziyad M Hijazi</dc:creator>
<dc:creator>Jamil A Aboulhosn</dc:creator>
<dc:creator>Daniel S Levi</dc:creator>
<dc:creator>Morris M Salem</dc:creator>
<dc:creator>Edwin Francis</dc:creator>
<dc:creator>Aleksander Kempny</dc:creator>
<dc:creator>Alain Fraisse</dc:creator>
<dc:creator>Carles Bautista-Rodriguez</dc:creator>
<dc:creator>Kevin Walsh</dc:creator>
<dc:creator>Damien Kenny</dc:creator>
<dc:creator>Brian Traynor</dc:creator>
<dc:creator>Salim N Al Maskari</dc:creator>
<dc:creator>James R Bentham</dc:creator>
<dc:creator>László Környei</dc:creator>
<dc:creator>Muthukumaran C Sivaprakasam</dc:creator>
<dc:creator>Ata Firouzi</dc:creator>
<dc:creator>Zahra Khajali</dc:creator>
<dc:creator>Lee Benson</dc:creator>
<dc:creator>Mark Osten</dc:creator>
<dc:creator>Alban-Elouen Baruteau</dc:creator>
<dc:creator>Matthew A Crystal</dc:creator>
<dc:creator>Thomas J Forbes</dc:creator>
<dc:creator>Stanimir Georgiev</dc:creator>
<dc:creator>Horst Sievert</dc:creator>
<dc:creator>Do Nguyen Tin</dc:creator>
<dc:creator>Daniel Springmuller</dc:creator>
<dc:creator>Anand Subramanian</dc:creator>
<dc:creator>Hussein A M Abdullah</dc:creator>
<dc:creator>Radwa Bedair</dc:creator>
<dc:creator>Francisco Chamié</dc:creator>
<dc:creator>Ahmet Celebi</dc:creator>
<dc:creator>Jesus Damsky Barbosa</dc:creator>
<dc:creator>Pieter De Meester</dc:creator>
<dc:creator>Luca Giugno</dc:creator>
<dc:creator>Zakaria Jalal</dc:creator>
<dc:creator>Clement Karsenty</dc:creator>
<dc:creator>Anastasia Schleiger</dc:creator>
<dc:creator>Gregory Fleming</dc:creator>
<dc:creator>Andre Jakob</dc:creator>
<dc:creator>Tevfik Karagoaz</dc:creator>
<dc:creator>Gur Mainzer</dc:creator>
<dc:creator>Gareth J Morgan</dc:creator>
<dc:creator>Nazmi Narin</dc:creator>
<dc:creator>Shabana Shahanavaz</dc:creator>
<dc:creator>Zachary L Steinberg</dc:creator>
<dc:creator>Osamah Aldoss</dc:creator>
<dc:creator>Elnur Alizade</dc:creator>
<dc:creator>Oliver Aregullin</dc:creator>
<dc:creator>Hélène Bouvaist</dc:creator>
<dc:creator>Thilo Fleck</dc:creator>
<dc:creator>Francois Godart</dc:creator>
<dc:creator>Sophie Malekzadeh-Milani</dc:creator>
<dc:creator>Paulo Motta</dc:creator>
<dc:creator>Angel Sanchez-Recalde</dc:creator>
<dc:creator>Juan Pablo Sandoval</dc:creator>
<dc:creator>Weiyi Tan</dc:creator>
<dc:creator>John Thomson</dc:creator>
<dc:creator>Pablo Tome</dc:creator>
<dc:creator>Evan M Zahn</dc:creator>
<dc:date>2024-12-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Covered Stent Correction for Sinus Venosus Atrial Septal Defects, an Emerging Alternative to Surgical Repair: Results of an International Registry</dc:title>
<dc:identifier>pmid:39697167</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070271</dc:identifier>
</item>
<item>
<title>YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39694037/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241220231241&amp;v=2.18.0.post9+e462414
      <description>Long-term durable remission in patients with B cell malignancies following chimeric antigen receptor (CAR)-T cell immunotherapy remains unsatisfactory, often due to antigen escape. Malignant B cell transformation and oncogenic growth relies on efficient ATP synthesis, although the underlying mechanisms remain unclear. Here, we report that YTHDF2 facilitates energy supply and antigen escape in B cell malignancies, and its overexpression alone is sufficient to cause B cell transformation and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 12:S0092-8674(24)01324-2. doi: 10.1016/j.cell.2024.11.007. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Long-term durable remission in patients with B cell malignancies following chimeric antigen receptor (CAR)-T cell immunotherapy remains unsatisfactory, often due to antigen escape. Malignant B cell transformation and oncogenic growth relies on efficient ATP synthesis, although the underlying mechanisms remain unclear. Here, we report that YTHDF2 facilitates energy supply and antigen escape in B cell malignancies, and its overexpression alone is sufficient to cause B cell transformation and tumorigenesis. Mechanistically, YTHDF2 functions as a dual reader where it stabilizes mRNAs as a 5-methylcytosine (m<sup>5</sup>C) reader via recruiting PABPC1, thereby enhancing their expression and ATP synthesis. Concomitantly, YTHDF2 also promotes immune evasion by destabilizing other mRNAs as an N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) reader. Small-molecule-mediated targeting of YTHDF2 suppresses aggressive B cell malignancies and sensitizes them to CAR-T cell therapy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39694037/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241220231241&v=2.18.0.post9+e462414">39694037</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.007>10.1016/j.cell.2024.11.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39694037</guid>
<pubDate>Wed, 18 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Zhenhua Chen</dc:creator>
<dc:creator>Chengwu Zeng</dc:creator>
<dc:creator>Lu Yang</dc:creator>
<dc:creator>Yuan Che</dc:creator>
<dc:creator>Meiling Chen</dc:creator>
<dc:creator>Lillian Sau</dc:creator>
<dc:creator>Bintao Wang</dc:creator>
<dc:creator>Keren Zhou</dc:creator>
<dc:creator>Yu Chen</dc:creator>
<dc:creator>Ying Qing</dc:creator>
<dc:creator>Chao Shen</dc:creator>
<dc:creator>Tingjian Zhang</dc:creator>
<dc:creator>Mark Wunderlich</dc:creator>
<dc:creator>Dong Wu</dc:creator>
<dc:creator>Wei Li</dc:creator>
<dc:creator>Kitty Wang</dc:creator>
<dc:creator>Keith Leung</dc:creator>
<dc:creator>Miao Sun</dc:creator>
<dc:creator>Tingting Tang</dc:creator>
<dc:creator>Xin He</dc:creator>
<dc:creator>Lianjun Zhang</dc:creator>
<dc:creator>Srividya Swaminathan</dc:creator>
<dc:creator>James C Mulloy</dc:creator>
<dc:creator>Markus Müschen</dc:creator>
<dc:creator>Huilin Huang</dc:creator>
<dc:creator>Hengyou Weng</dc:creator>
<dc:creator>Gang Xiao</dc:creator>
<dc:creator>Xiaolan Deng</dc:creator>
<dc:creator>Jianjun Chen</dc:creator>
<dc:date>2024-12-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies</dc:title>
<dc:identifier>pmid:39694037</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.007</dc:identifier>
</item>
<item>
<title>Potassium Nitrate in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39693096/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241220231241&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this study, potassium nitrate did not improve aerobic capacity, total work, or quality of life in participants with HFpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Dec 18. doi: 10.1001/jamacardio.2024.4417. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Nitric oxide deficiency may contribute to exercise intolerance in patients with heart failure with preserved ejection fraction (HFpEF). Prior pilot studies have shown improvements in exercise tolerance with single-dose and short-term inorganic nitrate administration.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess the impact of chronic inorganic nitrate administration on exercise tolerance in a larger trial of participants with HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This multicenter randomized double-blinded crossover trial was conducted at the University of Pennsylvania, the Philadelphia Veterans Affairs Medical Center, and Northwestern University between October 2016 and July 2022. Participants included patients with symptomatic (New York Heart Association class II/III) HFpEF who had objective signs of elevated left ventricular filling pressures. Image quantification, physiological data modeling and biochemical measurements, unblinding, and statistical analyses were completed in 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Potassium nitrate (KNO3) (6 mmol 3 times daily) vs equimolar doses of potassium chloride (KCl) for 6 weeks, each with a 1-week washout in between.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The coprimary end points included peak oxygen uptake and total work performed during a maximal effort incremental cardiopulmonary exercise test. Secondary end points included the exercise systemic vasodilatory reserve (ie, reduction in systemic vascular resistance with exercise) and quality of life assessed using the Kansas City Cardiomyopathy Questionnaire.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Eighty-four participants were enrolled. Median age was 68 years and 58 participants were women (69.0%). Most participants had NYHA class II disease (69%) with a mean 6-minute walk distance of 335.5 (SD, 97.3) m. Seventy-seven participants received the KNO3 intervention and 74 received the KCl intervention. KNO3 increased trough levels of serum nitric oxide metabolites after 6 weeks (KNO3, 418.4 [SD, 26.9] uM vs KCl, 40.1 [SD, 28.3] uM; P &lt; .001). KNO3 did not improve peak oxygen uptake (KNO3, 10.23 [SD, 0.43] mL/min/kg vs KCl, 10.17 [SD, 0.43] mL/min/kg; P = .73) or total work performed (KNO3, 25.9 [SD, 3.65] kilojoules vs KCl, 23.63 [SD, 3.63] kilojoules; P = .29). KNO3 nitrate did not improve the vasodilatory reserve or quality of life, though it was well-tolerated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this study, potassium nitrate did not improve aerobic capacity, total work, or quality of life in participants with HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02840799.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39693096/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241220231241&v=2.18.0.post9+e462414">39693096</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4417>10.1001/jamacardio.2024.4417</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39693096</guid>
<pubDate>Wed, 18 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Payman Zamani</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Jordana B Cohen</dc:creator>
<dc:creator>Manyun Zhao</dc:creator>
<dc:creator>Wei Yang</dc:creator>
<dc:creator>Jessica L Afable</dc:creator>
<dc:creator>Maria Caturla</dc:creator>
<dc:creator>Hannah Maynard</dc:creator>
<dc:creator>Bianca Pourmussa</dc:creator>
<dc:creator>Cassandra Demastus</dc:creator>
<dc:creator>Ipsita Mohanty</dc:creator>
<dc:creator>Michelle Menon Miyake</dc:creator>
<dc:creator>Srinath Adusumalli</dc:creator>
<dc:creator>Kenneth B Margulies</dc:creator>
<dc:creator>Stuart B Prenner</dc:creator>
<dc:creator>David C Poole</dc:creator>
<dc:creator>Neil Wilson</dc:creator>
<dc:creator>Ravinder Reddy</dc:creator>
<dc:creator>Raymond R Townsend</dc:creator>
<dc:creator>Harry Ischiropoulos</dc:creator>
<dc:creator>Thomas P Cappola</dc:creator>
<dc:creator>Julio A Chirinos</dc:creator>
<dc:date>2024-12-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Potassium Nitrate in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39693096</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4417</dc:identifier>
</item>
<item>
<title>Chest Pain in a Middle-Aged Man</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39693088/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241220231241&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Dec 18. doi: 10.1001/jamacardio.2024.4440. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39693088/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241220231241&v=2.18.0.post9+e462414">39693088</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4440>10.1001/jamacardio.2024.4440</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39693088</guid>
<pubDate>Wed, 18 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Qinghua Chang</dc:creator>
<dc:creator>Zhaolong Xu</dc:creator>
<dc:creator>Renguang Liu</dc:creator>
<dc:date>2024-12-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Chest Pain in a Middle-Aged Man</dc:title>
<dc:identifier>pmid:39693088</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4440</dc:identifier>
</item>
<item>
<title>Trajectory of Cardiovascular Health Across Childhood and Adolescence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39693062/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241220231241&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study provides insight into the trajectory of CVH early in life, which may contribute to CVH disparities in adulthood, and identified modifiable health behaviors for focused prevention efforts to optimize CVH in early life.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Dec 18. doi: 10.1001/jamacardio.2024.4022. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The American Heart Association put forth the Life's Essential 8 construct to assess cardiovascular health (CVH) based on 8 behavioral and health factors. Few studies have characterized the natural history of CVH in early life or identified its sociodemographic determinants.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To characterize CVH trajectories across childhood and adolescence and identify associations with sociodemographic variables.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This study used data from the Project Viva prebirth cohort, an ongoing prospective prebirth cohort study conducted in a large multispecialty group practice in eastern Massachusetts among women who were pregnant and enrolled from April 1999 to November 2002. Participant inclusion required 3 or more CVH metrics in early childhood (median [range] age, 3.2 [2.8-6.2] years) or 4 metrics or more in midchildhood (median [range] age, 7.7 [6.6-10.9] years), early adolescence (median [range] age, 13.0 [11.9-16.6] years), or late adolescence (median [range] age, 17.5 [15.4-20.1] years). Of 2218 live births in the original cohort, 1523 were included in the present analysis. Data were analyzed from June to December 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Child sex, race, and ethnicity; maternal education; and household income.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: CVH score (0-100 points) from early childhood to late adolescence, calculated as the unweighted average of all available CVH metrics at each life stage.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 1523 children, 782 (51.4%) were male; 53 (3.5%) were non-Hispanic Asian, 231 (15.2%) were non-Hispanic Black, 988 (65.0%) were non-Hispanic White, and 175 (11.5%) were non-Hispanic other. The mean (SD) CVH score was 82.6 (8.6) in early childhood, 84.1 (8.3) in midchildhood, 82.0 (9.8) in early adolescence, and 73.8 (11.5) in late adolescence. The estimated mean (SD) age of inflection when CVH score declined was 10.1 (0.7) years for male children and 10.0 (0.6) years for female children; the decline in CVH was associated with health behaviors rather than health factors. Male children (vs female children) had faster CVH score gain before the inflection (β, 0.79 points/year; 95% CI, 0.67 to 0.91) and faster CVH score decline after the inflection (β, -0.33 points/year; 95% CI, -0.44 to -0.22). Non-Hispanic Black children (β, 0.32 years; 95% CI, 0.20 to 0.43) and children of other non-Hispanic races (β, 0.16 years; 95% CI, 0.05 to 0.28) children had later timing of inflection compared with non-Hispanic White children. Children of mothers without (vs with) a college degree or with household income $70 000 per year or less (vs greater than $70 000/year) exhibited lower CVH trajectory throughout childhood. Children of mothers with some college education (vs a college degree) had later timing of inflection (β, 0.16 years; 95% CI, 0.07 to 0.26) and slower CVH score gain before the inflection (β, -0.24 points/year; 95% CI, -0.40 to -0.08).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study provides insight into the trajectory of CVH early in life, which may contribute to CVH disparities in adulthood, and identified modifiable health behaviors for focused prevention efforts to optimize CVH in early life.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39693062/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241220231241&v=2.18.0.post9+e462414">39693062</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4022>10.1001/jamacardio.2024.4022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39693062</guid>
<pubDate>Wed, 18 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Izzuddin M Aris</dc:creator>
<dc:creator>Sheryl L Rifas-Shiman</dc:creator>
<dc:creator>Wei Perng</dc:creator>
<dc:creator>Li Yi</dc:creator>
<dc:creator>Sarah D de Ferranti</dc:creator>
<dc:creator>Marie-France Hivert</dc:creator>
<dc:creator>Emily Oken</dc:creator>
<dc:date>2024-12-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Trajectory of Cardiovascular Health Across Childhood and Adolescence</dc:title>
<dc:identifier>pmid:39693062</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4022</dc:identifier>
</item>
<item>
<title>Preventing Declines in Cardiovascular Health From Childhood: Never Too Early for Heart Health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39693059/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241220231241&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Dec 18. doi: 10.1001/jamacardio.2024.4019. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39693059/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241220231241&v=2.18.0.post9+e462414">39693059</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4019>10.1001/jamacardio.2024.4019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39693059</guid>
<pubDate>Wed, 18 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Natalie A Cameron</dc:creator>
<dc:creator>Norrina B Allen</dc:creator>
<dc:date>2024-12-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Preventing Declines in Cardiovascular Health From Childhood: Never Too Early for Heart Health</dc:title>
<dc:identifier>pmid:39693059</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4019</dc:identifier>
</item>
<item>
<title>2024 ACC Expert Consensus Decision Pathway on Practical Approaches for Arrhythmia Monitoring After Stroke: A Report of the American College of Cardiology Solution Set Oversight Committee</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39692645/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241220231241&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 11:S0735-1097(24)10301-4. doi: 10.1016/j.jacc.2024.10.100. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39692645/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241220231241&v=2.18.0.post9+e462414">39692645</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.100>10.1016/j.jacc.2024.10.100</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39692645</guid>
<pubDate>Wed, 18 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Writing Committee</dc:creator>
<dc:creator>Michael T Spooner</dc:creator>
<dc:creator>Steven R Messé</dc:creator>
<dc:creator>Seemant Chaturvedi</dc:creator>
<dc:creator>Monika M Do</dc:creator>
<dc:creator>Ty J Gluckman</dc:creator>
<dc:creator>Janet K Han</dc:creator>
<dc:creator>Andrea M Russo</dc:creator>
<dc:creator>Sherry J Saxonhouse</dc:creator>
<dc:creator>Newton B Wiggins</dc:creator>
<dc:date>2024-12-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>2024 ACC Expert Consensus Decision Pathway on Practical Approaches for Arrhythmia Monitoring After Stroke: A Report of the American College of Cardiology Solution Set Oversight Committee</dc:title>
<dc:identifier>pmid:39692645</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.100</dc:identifier>
</item>
<item>
<title>ACKR1&lt;sup>;hi&lt;/sup>;ECs Promote Aortic Dissection Through Adjusting Macrophage Behavior</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39692014/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241220231241&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study reveals how endothelial cells exhibiting high ACKR1 expression modulate macrophage migration and proinflammatory polarization through the ACKR1/NF-κB/SPP1 signaling pathway, a crucial mechanism in TAAD progression. Targeting ACKR1 through both functional and pharmacological approaches effectively suppressed TAAD progression and extended survival in TAAD mice, offering promising new intervention strategies for clinical evaluation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Dec 18. doi: 10.1161/CIRCRESAHA.124.325458. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Type A aortic dissection (TAAD) is a life-threatening condition characterized by complex pathophysiology, in which macrophages play a critical but not yet fully understood role. This study focused on the role of endothelial cells with elevated expression of ACKR1 (atypical chemokine receptor 1) and their interaction with proinflammatory macrophages in TAAD development.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS AND RESULTS: Single-cell transcriptomic analysis of human aortic tissues revealed increased populations of endothelial cells exhibiting high ACKR1 expression and proinflammatory macrophages in TAAD samples. Both clinical and animal studies revealed that ACKR1 expression levels were strongly linked to TAAD severity. Gain- and loss-of-function studies demonstrated that ACKR1 promotes TAAD progression. Specific knockdown of ACKR1 in endothelial cells suppressed the NF-κB (nuclear factor-κB) signaling pathway and SPP1 (secreted phosphoprotein 1) expression, leading to reduced macrophage migration and proinflammatory polarization, which subsequently inhibited TAAD development. Conversely, ACKR1 overexpression accelerated TAAD progression. Notably, molecular docking and comprehensive evaluation identified amikacin as a potential novel modulator of ACKR1. Extensive in vitro and in vivo studies demonstrated that amikacin can regulate macrophage behavior through the ACKR1/NF-κB/SPP1 signaling pathway, thereby attenuating TAAD progression and improving survival rates in TAAD mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study reveals how endothelial cells exhibiting high ACKR1 expression modulate macrophage migration and proinflammatory polarization through the ACKR1/NF-κB/SPP1 signaling pathway, a crucial mechanism in TAAD progression. Targeting ACKR1 through both functional and pharmacological approaches effectively suppressed TAAD progression and extended survival in TAAD mice, offering promising new intervention strategies for clinical evaluation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39692014/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241220231241&v=2.18.0.post9+e462414">39692014</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325458>10.1161/CIRCRESAHA.124.325458</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39692014</guid>
<pubDate>Wed, 18 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Yayu Wang</dc:creator>
<dc:creator>Xiong Jia</dc:creator>
<dc:creator>Yifei Zhang</dc:creator>
<dc:creator>Bin Zhang</dc:creator>
<dc:creator>Yazhe Zhou</dc:creator>
<dc:creator>Xiaoru Li</dc:creator>
<dc:creator>Xiaoying Zhu</dc:creator>
<dc:creator>Jinquan Xia</dc:creator>
<dc:creator>Jun Ren</dc:creator>
<dc:creator>Chang Zou</dc:creator>
<dc:creator>Qijun Zheng</dc:creator>
<dc:date>2024-12-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>ACKR1&lt;sup>;hi&lt;/sup>;ECs Promote Aortic Dissection Through Adjusting Macrophage Behavior</dc:title>
<dc:identifier>pmid:39692014</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325458</dc:identifier>
</item>
<item>
<title>Follistatin From hiPSC-Cardiomyocytes Promotes Myocyte Proliferation in Pigs With Postinfarction LV Remodeling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39692006/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241220231241&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: ^(KO/OE)hiPSC-CM spheroids significantly improved cardiac function and reduced infarct size in pig hearts after ischemia/reperfusion injury by secreting follistatin, which upregulated HIPPO/YAP signaling and proliferation in endogenous pig cardiomyocytes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Dec 18. doi: 10.1161/CIRCRESAHA.124.325562. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: When human induced pluripotent stem cells (hiPSCs) that CCND2-OE (overexpressed cyclin-D2) were differentiated into cardiomyocytes (<sup>CCND2-OE</sup>hiPSC-CMs) and administered to the infarcted hearts of immunodeficient mice, the cells proliferated after administration and repopulated >;50% of the scar. Here, we knocked out human leukocyte antigen class I and class II expression in <sup>CCND2-OE</sup>hiPSC-CMs (<sup>KO/OE</sup>hiPSC-CMs) to reduce the cells' immunogenicity and then assessed the therapeutic efficacy of <sup>KO/OE</sup>hiPSC-CMs for the treatment of myocardial infarction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: <sup>KO/OE</sup>hiPSC-CM and wild-type hiPSC-CM (<sup>WT</sup>hiPSC-CM) spheroids were differentiated in shaking flasks, purified, characterized, and intramyocardially injected into pigs after ischemia/reperfusion injury; control animals were injected with basal medium. Cardiac function was evaluated via cardiac magnetic resonance imaging, and cardiomyocyte proliferation was assessed via immunostaining and single-nucleus RNA sequencing.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Measurements of cardiac function and scar size were significantly better in pigs treated with <sup>KO/OE</sup>hiPSC-CM spheroids than in animals treated with medium or <sup>WT</sup>hiPSC-CM spheroids. <sup>KO/OE</sup>hiPSC-CMs were detected for just 1 week after administration, but assessments of cell cycle activity and proliferation were significantly higher in the endogenous pig cardiomyocytes of the hearts from the <sup>KO/OE</sup>hiPSC-CM spheroid group than in those from the other 2 groups. Single-nucleus RNA-sequencing analysis identified a cluster of proliferating cardiomyocytes that was significantly more prevalent in the <sup>KO/OE</sup>hiPSC-CM spheroid-treated hearts (3.65%) than in the hearts from the medium (0.89%) or <sup>WT</sup>hiPSC-CM spheroid (1.33%) groups at week 1. YAP (Yes-associated protein) protein levels and nuclear localization were also significantly upregulated in pig cardiomyocytes after treatment with <sup>KO/OE</sup>hiPSC-CM spheroids. Follistatin, which interacts with the HIPPO/YAP pathway, was significantly more abundant in the medium from <sup>KO/OE</sup>hiPSC-CM spheroids than <sup>WT</sup>hiPSC-CM spheroids (30.29±2.39 versus 16.62±0.83 ng/mL, <i>P</i>=0.0056). Treatment with follistatin increased <sup>WT</sup>hiPSC-CM cell counts by 28.3% over 16 days in culture and promoted cardiomyocyte proliferation in the infarcted hearts of adult mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: <sup>KO/OE</sup>hiPSC-CM spheroids significantly improved cardiac function and reduced infarct size in pig hearts after ischemia/reperfusion injury by secreting follistatin, which upregulated HIPPO/YAP signaling and proliferation in endogenous pig cardiomyocytes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39692006/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241220231241&v=2.18.0.post9+e462414">39692006</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325562>10.1161/CIRCRESAHA.124.325562</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39692006</guid>
<pubDate>Wed, 18 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Yuhua Wei</dc:creator>
<dc:creator>Gregory Walcott</dc:creator>
<dc:creator>Thanh Nguyen</dc:creator>
<dc:creator>Xiaoxiao Geng</dc:creator>
<dc:creator>Bijay Guragain</dc:creator>
<dc:creator>Hanyu Zhang</dc:creator>
<dc:creator>Akazha Green</dc:creator>
<dc:creator>Manuel Rosa-Garrido</dc:creator>
<dc:creator>Jack M Rogers</dc:creator>
<dc:creator>Daniel J Garry</dc:creator>
<dc:creator>Lei Ye</dc:creator>
<dc:creator>Jianyi Zhang</dc:creator>
<dc:date>2024-12-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Follistatin From hiPSC-Cardiomyocytes Promotes Myocyte Proliferation in Pigs With Postinfarction LV Remodeling</dc:title>
<dc:identifier>pmid:39692006</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325562</dc:identifier>
</item>
<item>
<title>SGLT2 Inhibition Induces Cardioprotection by Increasing Parasympathetic Activity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39690446/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241220231241&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Dec 17. doi: 10.1161/CIRCRESAHA.124.324708. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39690446/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241220231241&v=2.18.0.post9+e462414">39690446</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324708>10.1161/CIRCRESAHA.124.324708</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39690446</guid>
<pubDate>Wed, 18 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Maryna V Basalay</dc:creator>
<dc:creator>Alla Korsak</dc:creator>
<dc:creator>Zhenhe He</dc:creator>
<dc:creator>Alexander V Gourine</dc:creator>
<dc:creator>Sean M Davidson</dc:creator>
<dc:creator>Derek M Yellon</dc:creator>
<dc:date>2024-12-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>SGLT2 Inhibition Induces Cardioprotection by Increasing Parasympathetic Activity</dc:title>
<dc:identifier>pmid:39690446</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324708</dc:identifier>
</item>
<item>
<title>Urinary tartaric acid as a biomarker of wine consumption and cardiovascular risk: the PREDIMED trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39689849/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241220231241&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Light-to-moderate wine consumption, measured through an objective biomarker (tartaric acid), was prospectively associated with lower CVD rate in a Mediterranean population at high cardiovascular risk.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 18:ehae804. doi: 10.1093/eurheartj/ehae804. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Moderate wine consumption has been associated with lower cardiovascular disease (CVD) risk in older populations. However, wine consumption information through self-reports is prone to measurement errors inherent to subjective assessments. The aim of this study was to evaluate the association between urinary tartaric acid, an objective biomarker of wine consumption, and the rate of a composite clinical CVD event.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A case-cohort nested study was designed within the PREDIMED trial with 1232 participants: 685 incident cases of CVD and a random subcohort of 625 participants (including 78 overlapping cases). Wine consumption was registered using validated food frequency questionnaires. Liquid chromatography-tandem mass spectrometry was used to measure urinary tartaric acid at baseline and after one year of intervention. Weighted Cox regression models were used to estimate hazard ratios (HRs) of CVD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Tartaric acid was correlated with self-reported wine consumption at baseline [r = 0.46 (95% CI 0.41; 0.50)]. Five categories of post hoc urinary tartaric acid excretion were used for better representation of risk patterns. Concentrations of 3-12 and 12-35 μg/mL, which reflect ∼3-12 and 12-35 glasses/month of wine, were associated with lower CVD risk [HR 0.62 (95% CI 0.38; 1.00), P = .050 and HR 0.50 (95% CI 0.27; 0.95), P = .035, respectively]. Less significant associations between self-reported wine consumption and CVD risk were observed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Light-to-moderate wine consumption, measured through an objective biomarker (tartaric acid), was prospectively associated with lower CVD rate in a Mediterranean population at high cardiovascular risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39689849/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241220231241&v=2.18.0.post9+e462414">39689849</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae804>10.1093/eurheartj/ehae804</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39689849</guid>
<pubDate>Tue, 17 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Inés Domínguez-López</dc:creator>
<dc:creator>Rosa M Lamuela-Raventós</dc:creator>
<dc:creator>Cristina Razquin</dc:creator>
<dc:creator>Camila Arancibia-Riveros</dc:creator>
<dc:creator>Polina Galkina</dc:creator>
<dc:creator>Jordi Salas-Salvadó</dc:creator>
<dc:creator>Ángel M Alonso-Gómez</dc:creator>
<dc:creator>Montserrat Fitó</dc:creator>
<dc:creator>Miquel Fiol</dc:creator>
<dc:creator>José Lapetra</dc:creator>
<dc:creator>Enrique Gómez-Gracia</dc:creator>
<dc:creator>José V Sorlí</dc:creator>
<dc:creator>Miguel Ruiz-Canela</dc:creator>
<dc:creator>Olga Castañer</dc:creator>
<dc:creator>Liming Liang</dc:creator>
<dc:creator>Lluis Serra-Majem</dc:creator>
<dc:creator>Frank B Hu</dc:creator>
<dc:creator>Emilio Ros</dc:creator>
<dc:creator>Miguel Ángel Martínez-González</dc:creator>
<dc:creator>Ramon Estruch</dc:creator>
<dc:date>2024-12-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Urinary tartaric acid as a biomarker of wine consumption and cardiovascular risk: the PREDIMED trial</dc:title>
<dc:identifier>pmid:39689849</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae804</dc:identifier>
</item>
<item>
<title>Wine consumption and cardiovascular health: the unresolved French paradox and the promise of objective biomarkers</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39689843/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241220231241&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 18:ehae726. doi: 10.1093/eurheartj/ehae726. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39689843/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241220231241&v=2.18.0.post9+e462414">39689843</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae726>10.1093/eurheartj/ehae726</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39689843</guid>
<pubDate>Tue, 17 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Giovanni de Gaetano</dc:creator>
<dc:creator>Simona Costanzo</dc:creator>
<dc:creator>Augusto Di Castelnuovo</dc:creator>
<dc:date>2024-12-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Wine consumption and cardiovascular health: the unresolved French paradox and the promise of objective biomarkers</dc:title>
<dc:identifier>pmid:39689843</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae726</dc:identifier>
</item>
<item>
<title>Lifetime risk of lower extremity peripheral arterial disease: a Danish nationwide longitudinal study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39688733/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241220231241&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: More than one in 10 Danish individuals are diagnosed with symptomatic PAD during their lifetime. Peripheral arterial disease diagnosis is associated with high morbidity and mortality at 1 and 5 years.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 17:ehae867. doi: 10.1093/eurheartj/ehae867. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Lower extremity peripheral arterial disease (PAD) presents a substantial disease burden, yet lifetime estimates remain scant. This nationwide study quantified the lifetime risk of PAD and its clinical outcomes in Denmark.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This cohort study included 4 275 631 individuals in Denmark aged 40-99 years between 1998 and 2018. We estimated the lifetime risk using a modified survival analysis method, considering death as a competing risk event.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Over a median 15.5-year follow-up, 151 846 individuals were diagnosed with PAD (median age at diagnosis 71.5 years, interquartile range 63.1-79.2). The overall lifetime risk of PAD from age 40 was 11.6% (95% confidence interval 11.6%-11.7%), decreasing from 12.9% in 1998-2002 to 10.7% in 2013-18. Males had a higher lifetime risk than females (12.8% vs. 10.5%). Socioeconomic disparities were evident, with higher risks for those with lower educational levels (risk difference 3.4%, 95% confidence interval 3.2%-3.6%) and lower income (risk difference 0.4%, 95% confidence interval 0.2%-0.5%). One year after PAD diagnosis, 21.4% had undergone lower limb revascularization, 8.0% had experienced a major amputation, and 16.2% had died. At 5 years, the corresponding proportions were 26.4%, 10.8%, and 40.8%, respectively. The risk of lower limb revascularization showed little variation by sex and socioeconomic status, whereas there was a strong socioeconomic gradient for major amputation and all-cause death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: More than one in 10 Danish individuals are diagnosed with symptomatic PAD during their lifetime. Peripheral arterial disease diagnosis is associated with high morbidity and mortality at 1 and 5 years.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39688733/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241220231241&v=2.18.0.post9+e462414">39688733</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae867>10.1093/eurheartj/ehae867</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39688733</guid>
<pubDate>Tue, 17 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Mette Søgaard</dc:creator>
<dc:creator>Christian-Alexander Behrendt</dc:creator>
<dc:creator>Nikolaj Eldrup</dc:creator>
<dc:creator>Flemming Skjøth</dc:creator>
<dc:date>2024-12-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Lifetime risk of lower extremity peripheral arterial disease: a Danish nationwide longitudinal study</dc:title>
<dc:identifier>pmid:39688733</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae867</dc:identifier>
</item>
<item>
<title>Diffusion tensor imaging to assess myocardial microstructure after infarction by magnetic resonance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39688390/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241220231241&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 17:ehae806. doi: 10.1093/eurheartj/ehae806. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39688390/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241220231241&v=2.18.0.post9+e462414">39688390</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae806>10.1093/eurheartj/ehae806</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39688390</guid>
<pubDate>Tue, 17 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Erica Dall'Armellina</dc:creator>
<dc:creator>Sven Plein</dc:creator>
<dc:date>2024-12-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Diffusion tensor imaging to assess myocardial microstructure after infarction by magnetic resonance</dc:title>
<dc:identifier>pmid:39688390</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae806</dc:identifier>
</item>





























</channel>
</rss>